An update from Haleon PLC Sponsored ADR ( (HLN) ) is now available.
On May 1, 2025, Haleon PLC announced that as of April 30, 2025, the total number of shares issued was 9,020,990,697, with 4,080,205 held as treasury shares. This results in 9,016,910,492 ordinary shares having voting rights, a figure crucial for shareholders and others with notification obligations under the FCA’s Disclosure Guidance and Transparency Rules. This announcement is significant for stakeholders as it provides clarity on the company’s share capital and voting rights, impacting how interests in the company are calculated and reported.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Outperform.
Haleon’s strong financial performance, characterized by robust cash flow and stable profitability, is a key strength, complemented by positive technical indicators suggesting upward momentum. However, the stock’s valuation appears high, and recent earnings call highlights both opportunities in emerging markets and challenges like FX headwinds and product performance issues. These factors collectively position the stock at a solid yet cautious 73.1 score.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC Sponsored ADR
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company’s product portfolio includes Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals and Supplements. Haleon is known for its trusted brands such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum.
YTD Price Performance: 7.64%
Average Trading Volume: 11,590,398
Technical Sentiment Signal: Sell
Current Market Cap: $45.17B
See more insights into HLN stock on TipRanks’ Stock Analysis page.